HABPHospital-Acquired Bacterial Pneumonia
HABPHyaluronic Acid-Binding Protein
HABPHigh Availability Business Partner (IBM)
HABPHarmful Algal Bloom Programme (Intergovernmental Oceanographic Commission; UNESCO)
HABPHigh Arterial Blood Pressure
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
A cross-sectional study designed from January 2013 till January 2014 included all 16 patients admitted to the ICU with HABP requiring mechanical ventilation for at least 48 hours in a general hospital in south of Iran were included.
To further identify the role of HA in ozone-induced inflammasome activation, we pretreated WT animals with HABP, which reduces the level of HA in the lungs (Garantziotis et al.
A second non-MAF HABP has also been demonstrated by immunohistochemistry on Microciona cell surfaces.
A total of 870 hospitalized adult patients with HABP or VABP were randomized and received trial medications comparing AVYCAZ 2.5 g (ceftazidime 2 grams and avibactam 0.5 grams) intravenously every eight hours to meropenem 1 gram intravenously every eight hours, said the company.
This prospective, randomised, double-blind, multicenter, non-inferiority, Phase 3 study assessed the safety and efficacy of Zerbaxa compared with meropenem in 726 adult patients diagnosed with either ventilated HABP or VABP requiring intravenous antibiotic therapy.
M2 EQUITYBITES-February 2, 2018-Allergan plc wins US FDA's approval for supplemental sNDA for the expanded use of AVYCAZ for HABP &VABP
The company said the clinical trial is designed to assess the intrapulmonary penetration and pharmacokinetics of ZOLYD to support future development for US patients with hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) infections, with a combined mortality rate of up to 33%.
Drug development company ICON plc (NasdaqGS:ICLR) said on Monday that it has won a US Food & Drug Administration (FDA) project to validate three Patient Reported Outcomes (PRO) instruments that will measure clinical endpoints in antibacterial drug trials of therapies for Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Community-Acquired Bacterial Pneumonia (CABP) and Hospital-Acquired Bacterial Pneumonia (HABP).
M2 PHARMA-February 2, 2018-Allergan plc wins US FDA's approval for supplemental sNDA for the expanded use of AVYCAZ for HABP &VABP
The firm requested Qualified Infectious Diseases Product designation for Iclaprim for two serious and life threatening infections, HABP and acute bacterial skin and skin structure infections.